sellWeak cluster of 210b5-1 plan
Michael Thomas Henderson sold $1.7M of APGE
Chief Executive Officer at Apogee Therapeutics, Inc.. 20,000 shares at an average of $83.38, traded Jun 10, 2026, filed Jun 12, 2026.
Warning score
38Value
$1.7M
20,000 shares
Holdings after
1,095,987
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$1.7M at market
- 0Share of holdings soldSold 1.8% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-26-073567, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | SOpen-market sale Common Stock10b5-1 | -6,770 | $82.21 | $557k | 1,109,217 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Common Stock10b5-1 | -7,654 | $82.78 | $634k | 1,101,563 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Common Stock10b5-1 | -1,080 | $84.18 | $91k | 1,100,483 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Common Stock10b5-1 | -1,577 | $85.19 | $134k | 1,098,906 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Common Stock10b5-1 | -2,305 | $86.27 | $199k | 1,096,601 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Common Stock10b5-1 | -614 | $86.89 | $53k | 1,095,987 | Jun 12, 2026 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $738k 5,500 shares | -3% | |
| 38Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $2.7M 20,000 shares | -2% | |
| 9Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $730k 5,500 shares | -3% | |
| 38Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $11M 80,000 shares | -7% | |
| 33Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $3.5M 26,400 shares | -13% | |
| 5Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $433k 5,500 shares | -3% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.6M 20,000 shares | -2% | |
| 12Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $463k 5,500 shares | -3% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $164k 2,000 shares | -1% | |
| 22Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $180k 2,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.